Khaled El-Adl

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 37

Top Topics

Molecular Docking

Breast Cancer Cells

Tyrosine Kinase

Capillary Electrophoresis

Top Venues

Archiv der Pharmazie

Journal of biomolecular structure & dynamics

Journal of enzyme inhibition and medicinal chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Ahmed K B Aljohani, Khaled El-Adl, Basmah Almohaywi, Omar M Alatawi, Marwa Alsulaimany, Ahmed El-Morsy, Sara A Almadani, Hussam Y Alharbi, Majed S Aljohani, Felemban Athary Abdulhaleem M, Hanan E M Osman, Samy Mohamady
Anticancer evaluations of iodoquinazoline substituted with allyl and/or benzyl as dual inhibitors of EGFR WT and EGFR T790M : design, synthesis, ADMET and molecular docking. RSC advances 14 (12) (2024)
Hatem Hussein Bayoumi, Mohamed-Kamal Ibrahim, Mohammed A Dahab, Fathalla Khedr, Khaled El-Adl
Exploration of the VEGFR-2 inhibition activity of phthalazine derivatives: design, synthesis, cytotoxicity, ADMET, molecular docking and dynamic simulation. RSC advances 14 (30) (2024)
Marwa Alsulaimany, Sanadelaslam S A El-Hddad, Zuhir S M Akrim, Ahmed K B Aljohani, Basmah Almohaywi, Omar M Alatawi, Sara A Almadani, Hussam Y Alharbi, Majed S Aljohani, Samar F Miski, Read Alghamdi, Khaled El-Adl
Exploration of cytotoxicity of iodoquinazoline derivatives as inhibitors of both VEGFR-2 and EGFR T790M : Molecular docking, ADMET, design, and syntheses. Archiv der Pharmazie (2024)
Sanadelaslam S A El-Hddad, Mohamed H Sobhy, Ahmed El-Morsy, Nabil A Shoman, Khaled El-Adl
Quinazolines and thiazolidine-2,4-dions as SARS-CoV-2 inhibitors: repurposing, in silico molecular docking and dynamics simulation. RSC advances 14 (19) (2024)
Sanadelaslam S A El-Hddad, Mohamed H Sobhy, Ahmed El-Morsy, Nabil A Shoman, Khaled El-Adl
Quinazolines and thiazolidine-2,4-dions as SARS-CoV-2 inhibitors: repurposing, in silico molecular docking and dynamics simulation. RSC advances 14 (19) (2024)
Hatem Hussein Bayoumi, Mohamed-Kamal Ibrahim, Mohammed A Dahab, Fathalla Khedr, Khaled El-Adl
Rationale, in silico docking, ADMET profile, design, synthesis and cytotoxicity evaluations of phthalazine derivatives as VEGFR-2 inhibitors and apoptosis inducers. RSC advances 14 (37) (2024)
Ahmed K B Aljohani, Khaled El-Adl, Basmah Almohaywi, Omar M Alatawi, Marwa Alsulaimany, Ahmed El-Morsy, Sara A Almadani, Hussam Y Alharbi, Majed S Aljohani, Felemban Athary Abdulhaleem M, Hanan E M Osman, Samy Mohamady
Anticancer evaluations of iodoquinazoline substituted with allyl and/or benzyl as dual inhibitors of EGFR WT and EGFR T790M : design, synthesis, ADMET and molecular docking. RSC advances 14 (12) (2024)
Hatem Hussein Bayoumi, Mohamed-Kamal Ibrahim, Mohammed A Dahab, Fathalla Khedr, Khaled El-Adl
Rationale, in silico docking, ADMET profile, design, synthesis and cytotoxicity evaluations of phthalazine derivatives as VEGFR-2 inhibitors and apoptosis inducers. RSC advances 14 (37) (2024)
Hatem Hussein Bayoumi, Mohamed-Kamal Ibrahim, Mohammed A Dahab, Fathalla Khedr, Khaled El-Adl
Exploration of the VEGFR-2 inhibition activity of phthalazine derivatives: design, synthesis, cytotoxicity, ADMET, molecular docking and dynamic simulation. RSC advances 14 (30) (2024)
Hazem Elkady, Khaled El-Adl, Helmy Sakr, Adel S Abdelraheem, Sally I Eissa, Mohamed Ayman El-Zahabi
Novel promising benzoxazole/benzothiazole-derived immunomodulatory agents: Design, synthesis, anticancer evaluation, and in silico ADMET analysis. Archiv der Pharmazie (2023)
Kurls E Anwer, Sanadelaslam S A El-Hddad, Nour E A Abd El-Sattar, Ahmed El-Morsy, Fathalla Khedr, Samy Mohamady, Doaa E Keshek, Samir A Salama, Khaled El-Adl, Noura S Hanafy
Five and six membered heterocyclic rings endowed with azobenzene as dual EGFR T790M and VEGFR-2 inhibitors: design, synthesis, in silico ADMET profile, molecular docking, dynamic simulation and anticancer evaluations. RSC advances 13 (50) (2023)
Mohamed Ayman El-Zahabi, Hazem Elkady, Helmy Sakr, Adel S Abdelraheem, Sally I Eissa, Khaled El-Adl
Design, synthesis, anticancer evaluation, in silico docking and ADMET analysis of novel indole-based thalidomide analogs as promising immunomodulatory agents. Journal of biomolecular structure & dynamics (2023)
Marwa Alsulaimany, Khaled El-Adl, Ahmed K B Aljohani, Hussam Y Alharbi, Omar M Alatawi, Majed S Aljohani, Ahmed El-Morsy, Sara A Almadani, Abdulrahman A Alsimaree, Samir A Salama, Doaa E Keshek, Abeer A Mohamed
Design, synthesis, docking, ADMET and anticancer evaluations of N -alkyl substituted iodoquinazoline derivatives as dual VEGFR-2 and EGFR inhibitors. RSC advances 13 (51) (2023)
Noura S Hanafy, Nada A A M Aziz, Sanadelaslam S A El-Hddad, Mohamed A Abdelgawad, Mohammed M Ghoneim, Amal F Dawood, Samy Mohamady, Khaled El-Adl, Sahar Ahmed
Design, synthesis, and docking of novel thiazolidine-2,4-dione multitarget scaffold as new approach for cancer treatment. Archiv der Pharmazie (2023)
Nada A A M Aziz, Riham F George, Khaled El-Adl, Walaa R Mahmoud
Design, synthesis, in silico docking, ADMET and anticancer evaluations of thiazolidine-2,4-diones bearing heterocyclic rings as dual VEGFR-2/EGFR T790M tyrosine kinase inhibitors. RSC advances 12 (20) (2022)
Mohamed S Alesawy, Mohamed-Kamal Ibrahim, Ibrahim H Eissa, Khaled El-Adl
Design, synthesis, in silico ADMET, docking, and antiproliferative evaluations of [1,2,4]triazolo[4,3-c]quinazolines as classical DNA intercalators. Archiv der Pharmazie 355 (4) (2022)
Nada A A M Aziz, Riham F George, Khaled El-Adl, Walaa R Mahmoud
Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations. Archiv der Pharmazie (2022)
Khaled El-Adl, Helmy M Sakr, Reda G Yousef, Ahmed B M Mehany, Hamada S Abulkhair, Ibrahim H Eissa
New quinoxalin-2(1H)-one-derived VEGFR-2 inhibitors: Design, synthesis, in vitro anticancer evaluations, in silico ADMET, and docking studies. Archiv der Pharmazie 355 (7) (2022)
Ibrahim H Eissa, Mohamed-Kamal Ibrahim, Mohamed S Alesawy, Khaled El-Adl
Antiproliferative evaluations of triazoloquinazolines as classical DNA intercalators: Design, synthesis, ADMET profile, and molecular docking. Archiv der Pharmazie 355 (5) (2022)
Khaled El-Adl, Mohamed-Kamal Ibrahim, Mohamed S Alesawy, Ibrahim H Eissa
Triazoloquinazoline derived classical DNA intercalators: Design, synthesis, in silico ADME profile, docking, and antiproliferative evaluations. Archiv der Pharmazie 355 (6) (2022)
Elwan Alaa, Helmy Sakr, Abdel-Ghany A El-Helby, Ahmed El-Morsy, Mohamed Abdelwahab Abdelgawad, Mohammed M Ghoneim, Mohamed El-Sherbiny, Khaled El-Adl
Triazoloquinoxalines-based DNA intercalators-Topo II inhibitors: design, synthesis, docking, ADMET and anti-proliferative evaluations. Journal of enzyme inhibition and medicinal chemistry 37 (1) (2022)
Nashwa M Saleh, Adel A H Abdel-Rahman, Asmaa M Omar, Mohamed M Khalifa, Khaled El-Adl
Pyridine-derived VEGFR-2 inhibitors: Rational design, synthesis, anticancer evaluations, in silico ADMET profile, and molecular docking. Archiv der Pharmazie 354 (8) (2021)
Hamada S Abulkhair, Salwa Elmeligie, Adel Ghiaty, Ahmed El-Morsy, Ashraf H Bayoumi, Hany E A Ahmed, Khaled El-Adl, Mohamed F Zayed, Memy H Hassan, Eman N Akl, Mona S El-Zoghbi
In vivo- and in silico-driven identification of novel synthetic quinoxalines as anticonvulsants and AMPA inhibitors. Archiv der Pharmazie 354 (5) (2021)
Fathalla Khedr, Mohamed-Kamal Ibrahim, Ibrahim H Eissa, Hamada S Abulkhair, Khaled El-Adl
Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations. Archiv der Pharmazie 354 (11) (2021)
Khaled El-Adl, Mohamed K Ibrahim, Fathalla Khedr, Hamada S Abulkhair, Ibrahim H Eissa
Design, synthesis, docking, and anticancer evaluations of phthalazines as VEGFR-2 inhibitors. Archiv der Pharmazie (2021)
Ahmed A Gaber, Ahmed M El-Morsy, Farag F Sherbiny, Ashraf H Bayoumi, Kamal M El-Gamal, Khaled El-Adl, Ahmed Ali Al-Karmalawy, Rogy R Ezz Eldin, Marwa A Saleh, Hamada S Abulkhair
Pharmacophore-linked pyrazolo[3,4-d]pyrimidines as EGFR-TK inhibitors: Synthesis, anticancer evaluation, pharmacokinetics, and in silico mechanistic studies. Archiv der Pharmazie (2021)
Khaled El-Adl, Helmy Sakr, Sanadelaslam S A El-Hddad, Abdel-Ghany A El-Helby, Mohamed Nasser, Hamada S Abulkhair
Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. Archiv der Pharmazie 354 (7) (2021)
Khaled El-Adl, Helmy Sakr, Mohamed Nasser, Mohamed Alswah, Fatma M A Shoman
5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations. Archiv der Pharmazie 353 (9) (2020)
Mohamed H El-Shershaby, Kamal M El-Gamal, Ashraf H Bayoumi, Khaled El-Adl, Hany E A Ahmed, Hamada S Abulkhair
Synthesis, antimicrobial evaluation, DNA gyrase inhibition, and in silico pharmacokinetic studies of novel quinoline derivatives. Archiv der Pharmazie 354 (2) (2020)
Khaled El-Adl, Mohamed-Kamal Ibrahim, Fathalla Khedr, Hamada S Abulkhair, Ibrahim H Eissa
N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies. Archiv der Pharmazie 354 (3) (2020)
Khaled El-Adl, Abdel-Ghany A El-Helby, Helmy Sakr, Rezk R Ayyad, Hazem A Mahdy, Mohamed Nasser, Hamada S Abulkhair, Sanadelaslam S A El-Hddad
Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. Archiv der Pharmazie 354 (2) (2020)
Khaled El-Adl, Abdel-Ghany A El-Helby, Helmy Sakr, Sanadelaslam S A El-Hddad
Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors. Archiv der Pharmazie 353 (8) (2020)
Ibrahim H Eissa, Ahmed M Metwaly, Amany Belal, Ahmed B M Mehany, Rezk R Ayyad, Khaled El-Adl, Hazem A Mahdy, Mohammed S Taghour, Kamal M A El-Gamal, Mohamad E El-Sawah, Souad A Elmetwally, Mostafa A Elhendawy, Mohamed M Radwan, Mahmoud A ElSohly
Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors. Archiv der Pharmazie 352 (11) (2019)
Abdel-Ghany A El-Helby, Helmy Sakr, Ibrahim H Eissa, Hamada Abulkhair, Ahmed A Al-Karmalawy, Khaled El-Adl
Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors. Archiv der Pharmazie 352 (10) (2019)
Abdel-Ghany A El-Helby, Rezk R A Ayyad, Mohamed F Zayed, Hamada S Abulkhair, Hazem Elkady, Khaled El-Adl
Design, synthesis, in silico ADMET profile and GABA-A docking of novel phthalazines as potent anticonvulsants. Archiv der Pharmazie 352 (5) (2019)
Abdel-Ghany A El-Helby, Helmy Sakr, Ibrahim H Eissa, Ahmed A Al-Karmalawy, Khaled El-Adl
Benzoxazole/benzothiazole-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations. Archiv der Pharmazie 352 (12) (2019)
Abdel-Ghany A El-Helby, Rezk R A Ayyad, Helmy Sakr, Khaled El-Adl, Mamdouh M Ali, Fathalla Khedr
Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR-2 Inhibitors. Archiv der Pharmazie 350 (12) (2017)